Clinical Trial

Ruxolitinib and Chidamide Intensified Bu/CY Conditioning Regimen

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to determine the efficacy and safety of Ruxolitinib and Chidamide intensified conditioning regimen in patients with Acute B cell Lymphoblast leukemia Underwenting Haploidenticl Peripheral blood Stem Cell Transplantation.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2021-10-20.
Trial Details
NCT Number NCT05088226
Lead Sponsor Chinese PLA General Hospital
Conditions Peripheral Blood Stem Cell Transplantation
Enrollment 50 participants
Start Date 2021-12-01
Primary Completion 2030-06-01 (estimated)
Study Completion 2031-06-01 (estimated)
Updated on ClinicalTrials.gov 2026-04-23